We found in the published literature (Table 2) that most studies showed that Ac-225-PSMA-617 had a good safety profile in the treatment of advanced PCa, with rare serious adverse events, even in patients of varying disease severity. Here, FOLH1 is linked to posterior cortical atrophy.